These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26171805)

  • 21. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
    Houslay MD
    Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
    Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
    J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are Erectile Dysfunction Medications Causally Related to Nonarteritic Anterior Ischemic Optic Neuropathy?
    Lee MS; Vaphiades M
    J Neuroophthalmol; 2016 Jun; 36(2):202-7. PubMed ID: 26828844
    [No Abstract]   [Full Text] [Related]  

  • 28. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
    Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
    Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
    Dorsey P; Keel C; Klavens M; Hellstrom WJ
    Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
    Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDE5 inhibitors for erectile dysfunction revisited.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):10-1. PubMed ID: 22354220
    [No Abstract]   [Full Text] [Related]  

  • 33. Nonarteritic Anterior Ischemic Optic Neuropathy and Erectile Dysfunction Drugs: Is There an Elephant in the Bedroom?
    Kruger JM; Pomeranz HD
    J Neuroophthalmol; 2017 Mar; 37(1):104-105. PubMed ID: 27984350
    [No Abstract]   [Full Text] [Related]  

  • 34. Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.
    Loeb S; Ventimiglia E; Salonia A; Folkvaljon Y; Stattin P
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
    Limin M; Johnsen N; Hellstrom WJ
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Advances in the studies of refractory erectile dysfunction].
    Wang BY; Jiang R
    Zhonghua Nan Ke Xue; 2013 Jan; 19(1):82-5. PubMed ID: 23469669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
    Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
    J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
    Loeb S; Lambe M; Stattin P
    J Urol; 2016 Apr; 195(4 Pt 1):1172-3. PubMed ID: 26783933
    [No Abstract]   [Full Text] [Related]  

  • 39. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.